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Reactive oxygen species (ROS) are formed in
oxidation of various cell constituents as DNA, lipids
and proteins and consequently cause oxidative dam-
age of cellular substance leading to cell death (1).
The oxidative damage of DNA induced by ROS lead
to certain cancers, and ROS may also play a role in
cell cycle progression. ROS are implicated in
numerous pathological events including metabolic
disorders, cellular aging, reperfusion damage of
DNA, inflammation and atherosclerosis (2). In that
light, searching for new, antioxidant agents seems to
be well grounded (3). It was demonstrated that
oxidative stress and reactive oxygen species produc-
tion are involved also in epilepsy pathogenesis. The
xanthone nucleus comprises an important class of
oxygenated heterocycles. They are found in natural
products, especially in higher plants, lichens and
fungi. Plants belonging to the Guttiferae family are
the richest in xanthone derivatives. The most popu-
lar is Garcinia mangostana, a tropical evergreen
tree. Its origin is in Southeast Asia. It can now be
found in Northern Australia, Brazil, Central
America, Hawaii, Southern India, Indonesia,
Malaysia, Thailand, and other tropical countries.
The edible fruit is deep reddish purple when ripe. In
Asia, it is known as the ìQueen of Fruitsî due to its
pleasant flavor (4). The fruitís hull of α-, β- and γ-
mangosteen, 3-isomangosteen, gartanin, 8-desoxy-
gartanin has been used for hundreds of years in
Southeast Asia as a medicine for skin infections,
wounds, dysentery and diarrhoea, but those biologi-
cal benefits were not related with the xanthone
structure (5). Nowadays, mangosteen is used as an
ingredient in several popular commercially available
nutritional supplements with antioxidant, cardiovas-
cular, immunestimulating activity, including
Vemma (Vemma Co.) and Xango (Xango Co.) (6).
It is known from the literature that xanthone deriva-
tives are characterized with diverse biological activ-
ities including tuberculostatic (7), antimicrobial (8),
cardiovascular (9), antiinflamatory (10) and antioxi-
dant (11, 12). Taking into account antioxidative
properties, compounds can act as metal chelators,
free radical scavengers, as well as inhibitors of lipid
peroxidation (13). There are evidences that oxida-
tive stress can be involved in seizure generation (14,
15). What is more, beneficial effects of antioxidants
in animal models of epileptic seizures was observed
(16), therefore, antioxidant properties could be rec-
ommended for newly synthesized antiepileptic com-
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pounds. New derivatives of xanthone are the subject
of the research carried out in our Department of
Bioorganic Chemistry. Anticonvulsant activity and
neurotoxicity were evaluated under the
Anticonvulsant Screening Program (ASP) at the
National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Bethesda,
USA.
Most of the structures mentioned below proved
their beneficial properties and were previously
described (17-20). Compounds 2 R,S; 2 R and 2 S
displayed significant anti-MES (maximal elec-
troshock) activity in mice with protective index
(TD50/ED50) of 5.84, 6.23 and 6.85, corresponding to
that of phenytoin, carbamazepine and valproate.
Moreover, compound 2 S revealed low micromolar
affinity to the voltage-dependent Ca2+ channels,
comparable to that of carbamazepine (17, 18).
Xanthone derivatives from the first series (1 S, 1 R,
1 R,S) were not so effective and acted in higher
doses than second series (2 R,S; 2 R and 2 S) (18,
19). 
Compound 3 R,S with chlorine atom at posi-
tion 7 in the xanthone scaffold was active in MES
Table 1. Xanthone derivatives containing chlorine in the aromatic ring and different alkyl substituent at the nitrogen atom.
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test in the dose of 30 mg/kg in 87% of the examined
mice (20). 
Herein we report on radical scavenging and
antioxidant activities of the synthesized xanthone
derivatives using 2,2-diphenyl-1-picrylhydrazyl
(DPPH) and ferric reducing antioxidant power
(FRAP) assays. 
MATERIALS AND METHODS
The reagents such as vitamin C, quercetin,
trolox, 2,2-diphenyl-1-picrylhydrazyl and 2,4,6-tri-
(2-pyridyl)-s-triazine were of analytical grade and
were obtained from Sigma-Aldrich Chemical
Company (Steinheim, Germany). All other reagents
(FeSO4, FeCl3 and methanol) were purchased from
Avantor Performance Materials Poland S.A.
Xanthone derivatives: (R/S)-1; (S)-1; (R)-1;
(R/S)-2; (S)-2; (R)-2; (R/S)-3 and 4 (Table 1) were
synthesized at the Department of Bioorganic
Chemistry, UJ CM, KrakÛw, Poland. Their struc-
tures were confirmed by 1H NMR and IR spectra
(17-20). Enantiomers were checked for their purity
by measuring their specific rotation (19, 20). For the
studies, compounds were dissolved in water using
ultrasounds and tested in the following concentra-
tions: 0.3, 0.6, 1, 50 and 200 µM. Reference antiox-
idants were used in the same concentrations as test-
ed compounds: L-ascorbic acid (vit. C, dissolved in
water), trolox (dissolved in methanol) and quercetin
(polyphenol dissolved in methanol). Spectrophoto-
meter Cecil CE 7200 BioAquarius (Cecil Instru-
ments Limited, Cambridge, UK) was applied for the
measurement of absorbance. Assays were carried
out in triplicate. Results are given as the means with
standard deviation. 
DPPH free radical scavenging activity assay
Antioxidant properties of the investigated
group of compounds were measured by DPPH test
based on the method reported by Blois (21). In gen-
eral, DPPH in its stable radical form absorbs at 517
nm, but upon reduction by an antioxidant present in
a sample its absorption decreases. Solution (0.6
mM) of 2,2-diphenyl-1-picryl-hydrazyl (DPPH) was
prepared in methanol. Fixed volume (25 µL) of solu-
tions of each compound or reference substance
(0.3ñ200 µM) were added to 1 mL of DPPH.
Solutions were mixed and incubated in dark at room
temperature for 30 min. After that time, the
absorbance of samples were measured at 517 nm
(As) against blank sample (methanol) (Ab). As a
control, absorbance of DPPH solution with 25 µL of
distilled water was measured (Ac). The capability of
tested compounds to scavenge the DPPH radical
(antioxidant activity) was calculated using the fol-
lowing equation: 
Ac ñ AsDPPH [%] = ññññññññññññ × 100
Ac ñ Ab
where Ac was the absorbance of the control, As of
the sample and Ab of the blank (methanol). 
Measurement of the total antioxidant capacity
The FRAP assay, which is the modification of
Benzie and Streinís method (22), was applied to
measure the ability of xanthone derivatives to
reduce Fe3+ to Fe2+ ions in acidic environment (pH
3.6). Fe2+ ions in the presence of 2,4,6-tripyridyl-S-
triazine (TPTZ) forms Fe2+-TPTZ intensive blue
complexes, with maximum absorbance at 593 nm.
Reaction mixture consisted of acetate buffer 0.3 M,
(pH 3.6); TPTZ 0.01 M and iron(III) chloride 0.02
M. Samples were prepared by adding 50 µL of test-
ed compound or standard in different concentrations
(0.3ñ200 µM) to 1 mL of reaction mixture. After
mixing, samples were incubated at 37OC for 30 min.
After that time, the absorbance was measured at a
wavelength of λ = 593 nm. Blank test was per-
formed similarly, but to a reaction mixture 50 µL of
distilled water was added. The antioxidant activity
was expressed in micromoles of ferrous ions per
liter produced by tested compound or standard,
Figure 1. DPPH [%] concentration values for the standard and xanthone derivatives of the series 1, 2 and substances 3R,S and 4
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which was calculated from the calibration curve of
iron(II) sulfate (100 to 1000 µM/L of FeSO4). 
RESULTS AND CONCLUSIONS
Number of reports concerning studies on
plant extracts from Garcinia rigida, Garcinia man-
gostana, Cudrania tricuspidata or Cratoxylum
cochinchinense demonstrated their various biolog-
ical activities, such as anti-inflammatory, antibac-
terial, antifungal, antioxidant, cytotoxic and anti-
HIV (23-26). Plants mentioned above are source of
xanthone derivatives, that were isolated and identi-
fied as (poly)phenols, possessing one or more
hydroxyl groups in the aromatic scaffold (27, 28).
Among synthetic xanthone derivatives, we report-
ed some compouds with promising anticonvulsant
properties being derivatives of 6- or 7-chloro-2-
(aminomethyl)-9H-xanthen-9-one. For this study,
we selected derivatives with defined anticonvul-
sant activity possessing hydroxyl group in the side
alkyl chain (Table 1). Their ability to ìsweep offî
free radicals was measured and expressed as a per-
centage of activity (DPPH test - Fig. 1). In case of
the FRAP method, production of Fe2+ in the pres-
ence of xanthone derivatives was calculated
(FRAP test - Fig. 2). 
Figure 1 illustrates a decrease in the concentra-
tion of DPPH due to the scavenging ability of xan-
thone derivatives and standards. The scavenging
effect decreased in the order of quercetin > vitamin
C > (R/S)-3 > (R)-1 > (R)-2 > trolox > 4 > (S)-1 >
(R/S)-1 > (S)-2 > (R/S)-2 yielding 63.5, 45.4, 31.7,
31.4, 27.6, 27.3, 26.6, 25.6, 20.6 and 15.6%, at the
concentration of 200 µM, respectively. Changing
concentrations of tested compounds from 200 to 50
µM resulted in greatest difference in outcomes for
all substances. In case of (R/S)-2, a decrease in scav-
enging activity was 67%, while for vit. C was only
32%. At the lowest tested concentration (0.3 µM)
the calculated scavenging activity for racemic (R/S)-
2 was of negative value, what can suggest pro-
oxidative properties of racemic compound. Such
effect was not observed in case of both of its enan-
tiomers (S)-2 and (R)-2. Comparing scavenging
effect of pairs of enantiomers and racemates (comp.
1 and 2) it can be readily observed that R-enan-
tiomers are more potent free radicals scavengers
(Fig. 1). We have previously reported some differ-
ences in free radical scavenging activity between
stereoisomers of β-carboline derivatives (29).
In case of FRAP assay, the highest Fe2+ content
in the tested samples was observed for compounds
(R)-1 and (R/S)-3 (Fig. 2). The reducing power of
these compounds was higher than all three reference
substances tested. Only at the highest concentration
(200 µM), vitamin C showed stronger antioxidative
activity than compound (R)-1, while quercetin at
concentration 1 µM more effectively reduced Fe3+
than (R/S)-3. Concerning chirality of xanthone
derivatives, both R-enantiomers ((R)-1 and (R)-2)
showed the tendency to increase value of FRAP
with the decrease of concentration. In case of stan-
dards, only vit. C decreased FRAP value when dilut-
ing samples, thus showing reducing properties. For
compound (S)-1, FRAP values did not significantly
differ in all of the tested concentrations. Compound
(R/S)-2 was the least active in the studied group of
xanthone derivatives. Generally (R)-enantiomers
showed stronger ferric reducing antioxidant power
than their (S)-enantiomers and racemates.
Additionaly, (R/S)-1 showed prooxidative proper-
ties at the lowest tested concentration (0.3 µM),
what overlapped with the observation in DPPH
assay. 
When comparing antioxidant activity of tested
compounds with their antiepileptic properties and
structure, most active in central nervous system
compound (S)-2 (17, 18) with chlorine atom in the
position of 6 and propanol as alkanol substituent,
Figure 2. FRAP [mM Fe2+/L] concentration values for the standard and investigated substances of the series 1, 2 and substances 3R,S and 4
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possessed only very mild antioxidant properties.
Racemic (R/S)-3, bearing chlorine in position 7 of
xanthone scaffold and butanol substituent at nitro-
gen atom, showed moderate anticonvulsant protec-
tion (19) and revealed the highest antioxidant effect
in tested series of compounds. On the other hand,
(R)-1, with chlorine substituent in position 6 of xan-
thone structure being tertiary amine with propanol
substituent and methyl group, exhibited the highest
ferric reduction power but in preliminary anticon-
vulsant screening was less effective than other com-
pounds (17, 18). 
In conclusion, the obtained results of antioxi-
dant studies for compounds affecting CNS functions
in the group of 2-(aminomethyl)-9H-xanthen-9-one
derivatives with alkanol substituent at the nitrogen
entitled to lead further studies to search for new
antiepileptic structure with good antioxidant proper-
ties. It requires of course more advanced methodol-
ogy. 
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